Applied Molecular Transport Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Rhea-AI Summary
Applied Molecular Transport Inc. (AMTI) reported third quarter 2020 results, highlighting the advancement of its AMT-101 Phase 2 clinical program targeting inflammatory bowel diseases and rheumatoid arthritis. The company initiated the LOMBARD trial for oral AMT-101 in ulcerative colitis, with more trials planned by year-end. R&D expenses increased to $13.4 million, and G&A expenses rose to $3.4 million, leading to a net loss of $16.8 million. As of September 30, 2020, cash and investments stood at $147.3 million.
Positive
- Initiated the LOMBARD trial for AMT-101 in ulcerative colitis.
- Expanded clinical trials for AMT-101 with additional Phase 2 studies planned.
- Strong cash position with $147.3 million available as of September 30, 2020.
Negative
- Net loss of $16.8 million for Q3 2020, up from $7.9 million in Q3 2019.
- R&D expenses increased significantly to $13.4 million, indicating higher financial burn.
News Market Reaction – AMTI
On the day this news was published, AMTI gained 1.53%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- Company on track with comprehensive AMT-101 Phase 2 clinical program across multiple indications, including inflammatory bowel diseases and rheumatoid arthritis -
- Announced dosing of first patient in Phase 2 monotherapy trial (LOMBARD) evaluating the efficacy and safety of oral AMT-101 in patients with moderate to severe ulcerative colitis -
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2020.
“We continue to make important progress in the development of our differentiated oral biologic drug candidates in a number of indications,” said Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT. “We recently advanced oral AMT-101 into a Phase 2 monotherapy trial in patients with ulcerative colitis (UC). In addition, we continue the planned expansion of this comprehensive clinical program with two additional Phase 2 trials of AMT-101 in combination with anti-TNFα therapy in biologic-naïve patients with moderate to severe UC and as a monotherapy in patients with pouchitis, both initiating by year-end. We are also looking forward to the initiation of the fourth Phase 2 trial for AMT-101 in combination with anti-TNFα in rheumatoid arthritis patients who are partially responding to anti-TNFα therapy. Furthermore, given the broad potential of our technology platform as an engine for the development of novel oral biologics, we continue to work on expanding our deep pipeline into additional indications and therapeutic areas and look forward to sharing updates on our progress.”
Recent Business Highlights
- Announced dosing of the first patient in the LOMBARD Phase 2 monotherapy trial evaluating the efficacy and safety of oral AMT-101 in patients with moderate to severe UC
- Successfully manufactured AMT-101 and AMT-126 clinical biologic drug supply at AMT’s internal GMP manufacturing facility
- Announced publication of preclinical data demonstrating potential of AMT-101 for inflammatory diseases in The Journal of Immunology (November 2020 issue)
Anticipated Upcoming Milestones
- Initiate the remaining Phase 2 trials for oral AMT-101:
- MARKET clinical trial of oral AMT-101 in combination with anti-TNFα, in biologic-naïve, moderate to severe UC patients by year-end
- FILLMORE clinical trial of oral AMT-101 for the treatment of pouchitis by year-end
- CASTRO clinical trial of oral AMT-101 in combination with anti-TNFα for the treatment of rheumatoid arthritis in 1H 2021
- Anticipate top-line data readouts from the four AMT-101 Phase 2 trials beginning in 2H 2021 and into 1H 2022
- File IND/CTA for AMT-126, a gastrointestinal (GI)-selective oral fusion of hIL-22, to treat serious diseases associated with intestinal epithelial (IE) barrier defects by year-end
Financial Results for the Third Quarter Ended September 30, 2020
Research and development (R&D) expenses. Total R&D expenses for the third quarter of 2020 were
General and administrative (G&A) expenses. Total G&A expenses for the third quarter of 2020 were
Net loss. Net loss for the third quarter of 2020 was
Cash, cash equivalents, and investments. As of September 30, 2020, cash, cash equivalents, and investments were
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly tablet and capsule forms that are designed to either target local GI tissue or enter systemic circulation to precisely address the relevant biology of a disease.
AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements including statements relating to AMT’s plans, expectations, forecasts and future events. Such forward-looking statements include, but are not limited to, the potential of, and expectations regarding AMT’s technology platform, statements regarding AMT’s Phase 2 clinical trials for AMT-101 including the timing of such trials, the timing of the filing of IND/CTA for AMT-126, AMT’s ability to leverage its technology to expand its pipeline, presentations regarding AMT-101’s Phase 1b dataset, and AMT-101 top-line data readouts including the timing of such readouts. In some cases, you can identify forward-looking statements by terminology such as “estimate,” “intend,” “may,” “plan,” “potentially,” “will” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our research programs; our ability to use and expand our technology platform to build a pipeline of product candidates; uncertainty of developing biologic therapeutics; our ability to advance product candidates into, and successfully complete, clinical trials; the timing or likelihood of regulatory filings and approvals; our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; the commercializing of our product candidates, if approved; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; future strategic arrangements and/or collaborations and the potential benefits of such arrangements; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified personnel; the implementation of our strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights, including our technology platform, product candidates and research programs; our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the pricing, coverage and reimbursement of our product candidates, if approved; developments relating to our competitors and our industry, including competing product candidates and therapies; potential delays and disruption resulting from the COVID-19 pandemic; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in AMT’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2020, and AMT’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and AMT assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Applied Molecular Transport Inc.
Condensed Balance Sheets
(unaudited)
(in thousands, except share and per share amounts)
| September 30, | December 31, | |||||||
| 2020 | 2019(*) | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 11,314 | $ | 12,727 | ||||
| Short-term investments | 135,940 | 19,676 | ||||||
| Prepaid expenses | 1,816 | 532 | ||||||
| Deferred offering costs | — | 366 | ||||||
| Other current assets | 79 | 152 | ||||||
| Total current assets | 149,149 | 33,453 | ||||||
| Property and equipment, net | 8,437 | 4,091 | ||||||
| Long-term investments | — | 249 | ||||||
| Restricted cash | 108 | 108 | ||||||
| Other assets | 127 | 632 | ||||||
| Total assets | $ | 157,821 | $ | 38,533 | ||||
| Liabilities, convertible preferred stock and stockholders’ equity (deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,705 | $ | 2,666 | ||||
| Accrued expenses | 4,692 | 1,315 | ||||||
| Deferred rent, current | 65 | 13 | ||||||
| Capital lease obligations, current | 229 | 42 | ||||||
| Total current liabilities | 7,691 | 4,036 | ||||||
| Deferred rent | 473 | 526 | ||||||
| Capital lease obligations | 463 | 58 | ||||||
| Total liabilities | 8,627 | 4,620 | ||||||
| Commitments and contingencies | ||||||||
| Series A convertible preferred stock, | — | 32,826 | ||||||
| Series B convertible preferred stock, | — | 30,921 | ||||||
| Series C convertible preferred stock, | — | 41,868 | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Common stock, | 3 | 1 | ||||||
| Additional paid-in capital | 269,437 | 1,078 | ||||||
| Accumulated other comprehensive income | 31 | 13 | ||||||
| Accumulated deficit | (120,277 | ) | (72,794 | ) | ||||
| Total stockholders’ equity (deficit) | 149,194 | (71,702 | ) | |||||
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $ | 157,821 | $ | 38,533 | ||||
(*) Derived from audited Financial Statements.
Applied Molecular Transport Inc.
Condensed Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 13,395 | $ | 6,890 | $ | 39,185 | $ | 17,756 | ||||||||
| General and administrative | 3,428 | 1,008 | 8,404 | 2,510 | ||||||||||||
| Total operating expenses | 16,823 | 7,898 | 47,589 | 20,266 | ||||||||||||
| Loss from operations | (16,823 | ) | (7,898 | ) | (47,589 | ) | (20,266 | ) | ||||||||
| Interest income, net | 59 | 36 | 187 | 107 | ||||||||||||
| Other expense, net | (29 | ) | (3 | ) | (81 | ) | (15 | ) | ||||||||
| Net loss | $ | (16,793 | ) | $ | (7,865 | ) | $ | (47,483 | ) | $ | (20,174 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.48 | ) | $ | (1.07 | ) | $ | (2.53 | ) | $ | (2.74 | ) | ||||
| Weighted-average shares of common stock outstanding, basic and diluted | 34,767,308 | 7,360,738 | 18,770,153 | 7,360,738 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (16,793 | ) | $ | (7,865 | ) | $ | (47,483 | ) | $ | (20,174 | ) | ||||
| Other comprehensive income (loss): | ||||||||||||||||
| Unrealized gains on investments | 29 | 3 | 37 | 3 | ||||||||||||
| Amounts recognized for net realized gains included in net loss | — | — | (19 | ) | — | |||||||||||
| Total comprehensive loss | $ | (16,764 | ) | $ | (7,862 | ) | $ | (47,465 | ) | $ | (20,171 | ) | ||||
Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com
Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What are the recent developments for AMTI's AMT-101?
What were AMTI's Q3 2020 financial results?
How much cash does AMTI have as of September 30, 2020?
What is the future outlook for AMTI's clinical trials?
